© 2020 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Waltham, MA-OXiGENE Inc. is launching a phase II clinical trial of its lead compound, Combretastatin A4 Prodrug (CA4P), in patients with myopic macular degeneration (MMD) under an investigational new drug application (NDA) submitted to the FDA.